Introduction Although minimally invasive techniques are currently recognized as effective and validated treatment for small gastric gastrointestinal stromal tumors (GISTs), the role of laparoscopy is not yet established, especially in the institutions that have less experience in minimally invasive surgery. Aim To evaluate the outcomes of laparoscopic treatment of gastric gastrointestinal stromal tumors compared to the results obtained in a group of patients treated with conventional surgery. Material and methods A retrospective analysis of data collected for a group of 68 patients treated for gastric GIST in the period from 2002 to 2017 was performed. Forty-six patients were treated laparoscopically (group 1) and 22 patients underwent conventional surgery (group 2). The analyzed medical data included clinical and pathomorphological features of removed tumors, perioperative parameters as well as short and long-term results of surgical treatment. Results Histopathological examination confirmed radical resection for all patients. No deaths were reported in the 30-day post-operative period. Patients in group 1 had significantly shorter length of hospital stay (3 vs. 9 days), less intra-operative blood loss (25 vs. 175 ml) and fewer perioperative complications (13% vs. 41%) compared to group 2. The mean post-operative follow-up was 57 months. During this period, four patients died for reasons unrelated to the primary disease. None of the patients who underwent a laparoscopic procedure had a recurrence of the tumor in the follow-up period. Conclusions Laparoscopy in the treatment of gastric GISTs has unquestionable advantages, including decreased blood loss, reduced risk of complications, and shorter hospital stay.

Introduction Laparoscopic sleeve gastrectomy (SG) is currently the most commonly performed bariatric operation, but re-do surgery may be necessary in up to half of the patients. Single anastomosis duodeno-ileal bypass (SADI-S) is quickly gaining recognition as a revisional procedure after failed SG. Aim To discuss the surgical technique and analyze initial outcomes after introduction of SADI-S after SG with 1-year follow-up. Material and methods This is a retrospective cohort study of consecutive patients who underwent re-do bariatric surgery – revisional SADI-S – in 2021 at a secondary referral public hospital. All patients’ follow-up was completed 1 year after. Results 14 consecutive patients, 6 (43%) males and 8 females, were included. Median maximal body mass index (BMI) was 52.29 (47.96–77.16) kg/m 2 , BMI before SADI-S was 43.09 (41.64–48.99) kg/m 2 . No perioperative morbidity was recorded. Four (28%) patients reported recurrent abdominal crampy pain and diarrhea that required dietary advisement and pharmacological therapy in the postoperative period. No reoperations, mortality or readmissions were recorded during 1-year follow-up. SADI-S was associated with further weight loss, resulting in median BMI of 37.55 (36.29–39.43) kg/m 2 1 year after SADI-S. Observed additional percentage total weight loss (%TWL) 1 year after SADI-S was 18.65% (17.25–21.89%), while additional percentage excess body mass index loss (%EBMIL) was 35.88% (29.18–41.92%). There was 1 case of diabetes mellitus type 2 remission and improvement in glycemic control in 1 patient. 4/6 patients (66.67%) had improvement in control of hypertension. Conclusions SADI-S is promising re-do surgery after SG with low postoperative morbidity. Additional %TWL 1 year after SADI-S is ~19%, while additional %EBMIL is ~36%, with significant improvement of obesity-related comorbidities.